Literature DB >> 23130541

Functional and oncological outcomes of primary versus salvage transoral laser microsurgery for supraglottic carcinoma.

Katherine A Hutcheson1, Kitti Jantharapattana, Denise A Barringer, Jan S Lewin, F Christopher Holsinger.   

Abstract

OBJECTIVES: We evaluated the functional and oncological outcomes of transoral laser microsurgery (TLM) in patients with previously untreated supraglottic carcinoma compared with the outcomes in salvage cases after radiation-based treatment.
METHODS: We conducted a retrospective case-control study at a single academic tertiary care institution. The functional outcomes were stratified by prior irradiation and were assessed at baseline, less than 1 week after operation, and at last follow-up.
RESULTS: Five patients underwent TLM for previously untreated disease, and 5 previously irradiated patients underwent salvage TLM for local failure. No patient required tracheostomy. There was no local recurrence after TLM as primary therapy, and none of those patients required radiotherapy. One salvage patient developed local recurrence. The duration of feeding tube dependence (p = 0.049) and the rates of chronic aspiration (more than 1 month after operation; p = 0.048) were significantly higher in the salvage TLM cases than in the previously untreated cases. The median scores on the PSS-HN Understandability of Speech were 75 ("usually understandable") in the salvage group and 100 ("always understandable") in the previously untreated group.
CONCLUSIONS: Both local control and function were better in the previously untreated patients than in the salvage patients. Our findings provide support for the use of TLM as a primary treatment modality for selected supraglottic carcinomas, but also suggest a potential for functional recovery in both previously untreated and salvage cases.

Entities:  

Mesh:

Year:  2012        PMID: 23130541      PMCID: PMC4047706          DOI: 10.1177/000348941212101007

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  23 in total

1.  Patterns of swallowing after supraglottic laryngectomy.

Authors:  J M Schweinfurth; S M Silver
Journal:  Laryngoscope       Date:  2000-08       Impact factor: 3.325

2.  Swallowing function after endoscopic resection of supraglottic carcinoma with the carbon dioxide laser.

Authors:  J Oeken; U Hänsch; S Thiel; F Bootz
Journal:  Eur Arch Otorhinolaryngol       Date:  2001-07       Impact factor: 2.503

3.  Voice, swallowing and quality of life in patients after transoral laser surgery for supraglottic carcinoma.

Authors:  Jong-Lyel Roh; Dong-Hyun Kim; Chan Il Park
Journal:  J Surg Oncol       Date:  2008-09-01       Impact factor: 3.454

4.  Swallowing outcomes after radiotherapy for laryngeal carcinoma.

Authors:  Katherine A Hutcheson; Denise A Barringer; David I Rosenthal; Annette H May; Dianna B Roberts; Jan S Lewin
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-02

5.  Voice and swallowing in patients enrolled in a larynx preservation trial.

Authors:  Elisabete Carrara-de Angelis; Olavo Feher; Ana Paula Brandao Barros; Ines Nobuko Nishimoto; Luiz Paulo Kowalski
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-07

6.  Transoral laser microsurgery for recurrent laryngeal and pharyngeal cancer.

Authors:  David G Grant; John R Salassa; Michael L Hinni; Bruce W Pearson; Richard E Hayden; William C Perry
Journal:  Otolaryngol Head Neck Surg       Date:  2008-05       Impact factor: 3.497

7.  CO2 laser treatment of supraglottic cancer.

Authors:  Gaetano Motta; Erik Esposito; Domenico Testa; Renata Iovine; Sergio Motta
Journal:  Head Neck       Date:  2004-05       Impact factor: 3.147

Review 8.  Swing of the pendulum: optimizing functional outcomes in larynx cancer.

Authors:  F Christopher Holsinger
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

9.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.

Authors:  Mitchell Machtay; Jennifer Moughan; Andrew Trotti; Adam S Garden; Randal S Weber; Jay S Cooper; Arlene Forastiere; K Kian Ang
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544

10.  Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709.

Authors:  Amit Agrawal; James Moon; R Kim Davis; Wael A Sakr; Shankar P G Giri; Joseph Valentino; Michael LeBlanc; John M Truelson; George H Yoo; John F Ensley; David E Schuller
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-10
View more
  5 in total

1.  Curative treatment of head and neck squamous cell carcinoma : Organ preservation strategies in clinical routine in German-speaking countries.

Authors:  T Kurzweg; J Kimmeyer; R Knecht; T K Hoffmann; C-J Busch; B B Lörincz; P J Schuler; S Laban
Journal:  HNO       Date:  2016-07       Impact factor: 1.284

Review 2.  Mechanisms of cryoablation: clinical consequences on malignant tumors.

Authors:  J G Baust; A A Gage; T E Bjerklund Johansen; J M Baust
Journal:  Cryobiology       Date:  2013-11-13       Impact factor: 2.487

Review 3.  Evidence and evidence gaps of laryngeal cancer surgery.

Authors:  Susanne Wiegand
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

Review 4.  Salvage Transoral Laser Microsurgery for Radiorecurrent Laryngeal Cancer: Indications, Limits, and Outcomes.

Authors:  J Meulemans; P Delaere; S Nuyts; P M Clement; R Hermans; V Vander Poorten
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-02-07

5.  Salvage carbon dioxide transoral laser microsurgery for laryngeal cancer after (chemo)radiotherapy: a European Laryngological Society consensus statement.

Authors:  Cesare Piazza; Alberto Paderno; Elisabeth V Sjogren; Patrick J Bradley; Hans E Eckel; Antti Mäkitie; Nayla Matar; Vinidh Paleri; Giorgio Peretti; Roberto Puxeddu; Miquel Quer; Marc Remacle; Vincent Vander Poorten; Isabel Vilaseca; Ricard Simo
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-05       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.